{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T01:03:12Z","timestamp":1789261392352,"version":"build-2803163510"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T00:00:00Z","timestamp":1662163200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007659","name":"Bayer HealthCare Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004361","name":"Krebsliga Schweiz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004361","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007352","name":"Staatssekretariat f\u00fcr Bildung, Forschung und Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007352","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013362","name":"Swiss Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013362","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.lungcan.2022.08.016","type":"journal-article","created":{"date-parts":[[2022,8,28]],"date-time":"2022-08-28T00:53:14Z","timestamp":1661647994000},"page":"154-159","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19\/18 phase II study"],"prefix":"10.1016","volume":"172","author":[{"given":"Alfredo","family":"Addeo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sacha I.","family":"Rothschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Holer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Waibel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Haefliger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Mach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Mauti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip M.","family":"Jermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Alborelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byron","family":"Calgua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spasenija","family":"Savic-Prince","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Joerger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Fr\u00fch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.lungcan.2022.08.016_b0005","doi-asserted-by":"crossref","first-page":"16052","DOI":"10.18632\/oncotarget.14109","article-title":"Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application","volume":"8","author":"Chae","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.lungcan.2022.08.016_b0010","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00345-007-0213-4","article-title":"Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target","volume":"25","author":"Knowles","year":"2007","journal-title":"World J. Urol."},{"issue":"4","key":"10.1016\/j.lungcan.2022.08.016_b0015","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/hmg\/dds486","article-title":"Oncogenic FGFR3 gene fusions in bladder cancer","volume":"22","author":"Williams","year":"2013","journal-title":"Hum. Mol. Genet."},{"issue":"4","key":"10.1016\/j.lungcan.2022.08.016_b0020","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/hep.26890","article-title":"Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma","volume":"59","author":"Arai","year":"2014","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.lungcan.2022.08.016_b0025","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","article-title":"The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing","volume":"22","author":"Helsten","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.lungcan.2022.08.016_b0030","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1097\/JTO.0b013e31826aed28","article-title":"FGFR1 amplification in squamous cell carcinoma of the lung","volume":"7","author":"Heist","year":"2012","journal-title":"J. Thorac. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2022.08.016_b0035","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1038\/modpathol.2012.102","article-title":"Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer","volume":"25","author":"Schildhaus","year":"2012","journal-title":"Mod. Pathol."},{"issue":"24","key":"10.1016\/j.lungcan.2022.08.016_b0040","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1158\/1078-0432.CCR-12-2694","article-title":"Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models","volume":"18","author":"Zhang","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.lungcan.2022.08.016_b0045","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(19)30412-7","article-title":"Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study","volume":"20","author":"Schuler","year":"2019","journal-title":"Lancet Oncol."},{"issue":"18","key":"10.1016\/j.lungcan.2022.08.016_b0050","doi-asserted-by":"crossref","first-page":"5366","DOI":"10.1158\/1078-0432.CCR-17-0645","article-title":"A phase Ib open-label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers","volume":"23","author":"Paik","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.lungcan.2022.08.016_b0055","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1200\/JCO.2016.67.2048","volume":"35","author":"Nogova","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2022.08.016_b0060","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/cmdc.201700718","article-title":"Discovery of rogaratinib (BAY 1163877): a pan-FGFR inhibitor","volume":"13","author":"Collin","year":"2018","journal-title":"ChemMedChem"},{"issue":"7","key":"10.1016\/j.lungcan.2022.08.016_b0065","doi-asserted-by":"crossref","first-page":"e241","DOI":"10.1038\/oncsis.2016.48","article-title":"Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy","volume":"5","author":"Kim","year":"2016","journal-title":"Oncogenesis"},{"issue":"7417","key":"10.1016\/j.lungcan.2022.08.016_b0070","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature11404","article-title":"Comprehensive genomic characterization of squamous cell lung cancers","volume":"489","author":"N. Cancer Genome Atlas Research","year":"2012","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.lungcan.2022.08.016_b0075","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.jtho.2019.05.041","article-title":"SWOG S1400D (NCT02965378), a phase II study of the fibroblast growth factor receptor inhibitor AZD4547 in previously treated patients with fibroblast growth factor pathway-activated stage IV squamous cell lung cancer (lung-MAP substudy)","volume":"14","author":"Aggarwal","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2022.08.016_b0080","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.canlet.2018.02.015","article-title":"The Hippo\/YAP1 pathway interacts with FGFR1 signaling to maintain stemness in lung cancer","volume":"423","author":"Lu","year":"2018","journal-title":"Cancer Lett."},{"issue":"10","key":"10.1016\/j.lungcan.2022.08.016_b0085","doi-asserted-by":"crossref","first-page":"7899","DOI":"10.18632\/oncotarget.3219","article-title":"Upregulated lncRNA-UCA1 contributes to progression of hepatocellular carcinoma through inhibition of miR-216b and activation of FGFR1\/ERK signaling pathway","volume":"6","author":"Wang","year":"2015","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.lungcan.2022.08.016_b0090","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-12-0210","article-title":"FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor","volume":"2","author":"Guagnano","year":"2012","journal-title":"Cancer Discov."},{"issue":"7","key":"10.1016\/j.lungcan.2022.08.016_b0095","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s40618-020-01205-9","article-title":"Phosphate-sensing and regulatory mechanism of FGF23 production","volume":"43","author":"Takashi","year":"2020","journal-title":"J. Endocrinol. Invest."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500222006055?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500222006055?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:03:37Z","timestamp":1759237417000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500222006055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":19,"alternative-id":["S0169500222006055"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2022.08.016","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19\/18 phase II study","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2022.08.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}